Advertisement

Topics

Ipsen Announces Co-Promotion Agreement With Saol Therapeutics To Promote Dysport (abobotulinumtoxinA) in the United States

08:07 EDT 30 Jun 2017 | FinanzNachrichten

Saol sales team to promote Dysport for select approved therapeutic indications in U.S. hospitals Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that its US affiliate has entere...

Original Article: Ipsen Announces Co-Promotion Agreement With Saol Therapeutics To Promote Dysport (abobotulinumtoxinA) in the United States

NEXT ARTICLE

More From BioPortfolio on "Ipsen Announces Co-Promotion Agreement With Saol Therapeutics To Promote Dysport (abobotulinumtoxinA) in the United States"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...